Taran Therapeutics Reports Publication from PREACH-M Trial for Chronic Myelomonocytic Leukemia in Current Edition of the European Medical Journal

July 28, 2025 8:00 AM

Taran Therapeutics ("Taran") a privately held company focused on hematology/oncology, announced the publication of a paper entitled ‘Durable Responses to Lenzilumab: Azacitidine Combination Therapy in High Risk Proliferative Chronic Myelomonocytic Leukaemia with Suppression of CBL and RAS Mutant Subclones' in the July 2025 edition of the European Medical Journal, Hematology edition.The paper reports on the PREACH-M study assessment to date with...

Read more

Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025

July 28, 2025 2:50 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and will jointly present a poster on updated data from the Phase 1 part of the Phase 1/2a study of...

Read more

Alligator Bioscience Announces Upcoming Presentation of REACtiVe-2 Phase 1 Data at ESMO Congress 2025

July 25, 2025 6:35 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announces that data from the Phase 1 REACtiVe-2 trial ( NCT05650918 ) of the CD40 agonist mitazalimab in combination with dendritic cell vaccination (Amphera's MesoPher) will be presented at the European Society for Medical Oncology (ESMO) Congress 2025, taking place on 17-21 October in Berlin,...

Read more

Elizabeth Fraley Kinder Ready Tackles Summer Brain Drain with Targeted Learning Support for Children

July 25, 2025 5:30 AM

As the summer months dragged on, educators and parents found themselves facing the same challenge.. This challenge, known as the "summer brain drain," refers to the fact that students lose academic progress during extended periods away from structured learning. To address this problem, Elizabeth Fraley Kinder Ready is focusing on the continuity of early learning through the Kinder Ready tutoring model. Those programs not only maintain pre-K and...

Read more

Kinder Ready Elizabeth Fraley Is Boosting Confidence Through Summer Learning With Proven Tutoring Strategies

July 25, 2025 4:50 AM

For many young children, summertime is a time for fun and trying out new things. However, school smarts can slide a bit. Elizabeth Fraley Kinder Ready gets this. They have created a summer learning plan to keep kids on track, build their confidence, and prepare them for the upcoming school year. They use Kinder Ready tutoring that works for each family to keep learning going strong while still having summer fun.Filling the Summer Learning void...

Read more

Biovica Launches DiviTum(R) TKa for Use in Early Breast Cancer

July 25, 2025 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, today announces the launch of DiviTum Tka for use in early breast cancer for patients undergoing adjuvant therapy, available as a laboratory developed test (LDT) from its CLIA-certified laboratory in the US. The launch opens a new market indication, representing a potential fivefold expansion of the addressable market for DiviTum TKa."...

Read more

CDx Diagnostics Receives FDA Breakthrough Device Designation for Its WATS3D Test System for Esophageal Cancer

July 24, 2025 1:30 PM

CDx Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for its proprietary WATS3D diagnostic system, a ‘first-of-a-kind' AI-powered digital pathology system using wide area transepithelial sampling for the diagnosis of Barrett's esophagus and early neoplastic alterations in patients at risk for disease progression."The Breakthrough Device Designation recognizes what the volume of...

Read more

Biovica Awarded 3 MSEK Contract - 4th from Leading Tier-1 Pharma Company

July 24, 2025 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announced its fourth's work order with this Tier-1 pharmaceutical customer. This order is valued at approximately SEK 3 million. The project is expected to be fully executed during fall 2025.This order extends the portfolio of ~25 MSEK in projects agreed with pharma companies active in developing new cancer treatments supported...

Read more

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

July 23, 2025 10:15 PM

Tharimmune, Inc. (the "Company" and "Tharimmune") (Nasdaq Capital Market:THAR), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced the pricing of a registered direct public offering (the "RD Offering") with certain purchasers, under the Shelf Registration Statement (as defined below), of up to $1.74 million of the Company's securities (the "Securities") consisting of (i)...

Read more

ClearPoint Neuro to Announce Second Quarter 2025 Results August 12, 2025

July 23, 2025 4:05 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2025 second quarter on Tuesday, August 12th, after the market close.Investors and analysts are invited to listen to the live broadcast review of the Company's 2025 second quarter on Tuesday, August 12th at 4:30 p.m. Eastern...

Read more

BioLumic Appoints AgTech Veteran Greg Levow as COO to Scale Light-Activated Seed Trait Platform

July 23, 2025 11:30 AM

BioLumic, a pioneer in seed trait innovation, has appointed Greg Levow as Chief Operating Officer. Levow joins the executive team to scale commercial operations and delivery as BioLumic expands the xTraits™ platform across key crops and global markets. As COO, Levow will guide company operations, delivery infrastructure, and partner-facing execution, working closely with BioLumic's science, product, and commercial teams to scale its seed trait...

Read more

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

July 23, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced the presentation of three scientific posters at the 2025 Alzheimer's Association International Conference ("AAIC"), taking place July 27-31 in Toronto, Canada. The poster presentations highlight advancements in the Company's proprietary artificial intelligence ("AI") platforms designed to accelerate drug discovery and...

Read more

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

July 23, 2025 8:30 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has continued its collaboration with The Scripps Research Institute ("TSRI") to advance the development of the Company's development program evaluating the combination of systemic DNase I and CAR T-cell therapies.Xenetic's...

Read more

eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months

July 22, 2025 4:10 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - together with its spinout NCTx, announced a breakthrough in biomanufacturing using their cell-free exozyme platform: From proof-of-concept to lab scale validation with gram-scale production in only 5 months.This critical technical milestone validates the...

Read more

Lingyi Biotech Advances Next-Generation Gene Therapies

July 22, 2025 3:15 PM

Lingyi Biotech, a clinical-stage biotechnology company specializing in gene therapies for rare diseases, announced key clinical milestones at the 2025 American Society of Gene & Cell Therapy (ASGCT) annual meeting in New Orleans. The company highlighted its lead investigational programs, LY-M001 for Gaucher disease and LY-M003 for Wilson disease, both built on its next-generation AAV2.0 platform.Dr. Yixiong Chen, CSO; Dr. Andrew Lin, Founder and...

Read more

enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

July 22, 2025 8:45 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Rob Berman, CEO of enVVeno, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. As part of the segment, Mr. Berman dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he...

Read more

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

July 21, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that its Principal Scientist, Jagadeesh Rao, Ph.D., has been awarded the Best Researcher Award at the 11th Annual World Neuroscientist Awards.Dr. Rao was selected through a rigorous evaluation by an international panel of academic and industry experts in clinical drug development and neuroscience research. The award...

Read more

Taran Therapeutics Presents Promising Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia and Secondary Acute Myeloid Leukemia Treatment

July 21, 2025 8:00 AM

Taran Therapeutics ("Taran") a privately held company focused on hematology/oncology, announced additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS-pathway mutations, building on data presented at the European Hematology Association meeting recently held in...

Read more

FluoGuide Enters Collaboration with Global MedTech Company Olympus

July 21, 2025 8:00 AM

FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces a collaboration with Olympus, a global medical technology company.At FluoGuide, our mission is to help patients with cancer by improving precision surgery. Our lead product, FG001, has been clinically proven to light up cancer and guide surgeons in performing more precise surgeries.The objective of the collaboration is...

Read more

Lee A. Tafoya Says Rethinking Patient-Centered Care Starts with Your Lab Partner

July 21, 2025 4:00 AM

In the ongoing conversation around patient-centered care, attention often gravitates toward physicians, electronic records, or bedside manner. However, Lee A. Tafoya, Business Development Executive at Midwest Innovation Laboratory, is urging healthcare professionals to look deeper into the infrastructure behind clinical decision-making. He believes that diagnostic laboratories, while rarely visible to the patient, are central to the quality of...

Read more